Reviva Pharmaceuticals (NASDAQ:RVPH) Earns “Buy” Rating from HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $4.00 price objective on the stock.

Several other analysts have also issued reports on the company. Chardan Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Benchmark dropped their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a research report on Monday, September 15th. D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday, October 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Trading Down 45.5%

Shares of NASDAQ RVPH opened at $0.32 on Tuesday. The firm has a market cap of $36.97 million, a P/E ratio of -0.70 and a beta of -0.02. The business’s 50 day moving average is $0.57 and its 200-day moving average is $0.52. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $2.17.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. Analysts forecast that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals in the second quarter valued at about $31,000. Lido Advisors LLC bought a new position in Reviva Pharmaceuticals during the 3rd quarter worth approximately $37,000. NewEdge Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals in the 1st quarter worth approximately $58,000. Geode Capital Management LLC boosted its stake in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. Finally, Persistent Asset Partners Ltd raised its stake in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock worth $244,000 after buying an additional 480,864 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Key Stores Impacting Reviva Pharmaceuticals

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: Large, unusual call?option activity — Investors bought roughly 25,745 call options (?+295% vs. average), suggesting speculative bullish bets or hedging that could provide short?term buying support. Traders Purchase High Volume of Call Options on Reviva Pharmaceuticals
• Positive Sentiment: Analyst support remains — D. Boral Capital reaffirmed a “buy” rating and a $2.00 price target, signaling at least one analyst believes recovery upside exists from current levels. D Boral Capital maintains Reviva Pharmaceuticals Holdings (RVPH) buy recommendation
• Negative Sentiment: FDA requested a second Phase 3 trial for brilaroxazine — The company disclosed written FDA feedback recommending an additional Phase 3 to generate more efficacy/safety data before an NDA submission, a major regulatory delay and cost driver. Reviva Announces Regulatory Update
• Negative Sentiment: Material funding need implied — Roth Capital estimates Reviva may require an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing risk for shareholders. Roth says Reviva may need additional $60M-$75M for schizophrenia study
• Negative Sentiment: Price target cut and market reaction — Roth lowered its price target to $1.50 from $3, and coverage highlighted an immediate sell?off after the FDA news; those moves reflect diminished near?term valuation and higher perceived execution risk. Reviva Pharmaceuticals price target lowered to $1.50 from $3 at Roth Capital
• Negative Sentiment: Market headlines and coverage explain the sharp drop — Multiple outlets reported the stock plunge and explained the catalyst as the FDA request and funding concerns, which can amplify selling pressure. Reviva stock plunges after FDA requests second Phase 3 Why did RVPH stock crash 50% today?

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.